Latest Factor VIII Stories
Octapharma has been committed to innovative patient care programs since inception and industry partnerships are central to the biopharmaceutical company's mission. As the most common inherited bleeding disorder in humans, von Willebrand Disease (VWD) affects one to two percent of the general population or approximately 3 million people in the United States. The severity of VWD is highly variable, from severe cases in which the tendency for excessive bleeding is obvious and treatment...
HOBOKEN, N.J., Dec. 8, 2010 /PRNewswire/ -- Octapharma USA researchers presented new stringent, objective criteria used in the evaluation of hemostatic efficacy in the treatment of von Willebrand disease (VWD) and reported on their application of these criteria in clinical trials during the recently completed National Hemophilia Foundation (NHF) Annual Meeting. According to the National Institutes of Health VWD is the most common inherited bleeding disorder and occurs in about 1 out of...
KING OF PRUSSIA, Pa., Dec. 1, 2010 /PRNewswire/ -- CSL Behring announced today the availability of the next generation HeliTrax® System as part of a specially designed software platform for Apple's iPhone®, iPod touch®, or iPad(TM) devices. This enhanced system is designed to improve therapy management for people with hemophilia A who use CSL Behring's recombinant factor VIII (rFVIII). The new HeliTrax software is designed with an interface that ensures compatibility with both Lab...
HOBOKEN, N.J., Nov. 8, 2010 /PRNewswire/ -- Octapharma USA is proud to support educational initiatives for von Willebrand Disease (VWD), the most common inherited bleeding disorder, at the 62nd Annual Meeting of the National Hemophilia Foundation (NHF) scheduled for Nov. 11-13 in New Orleans. In addition to supporting several educational symposia discussing VWD, Octapharma will also provide poster presentations that will assist in increasing awareness of current research for the treatment...
LAGUNA NIGUEL, Calif., Nov. 5, 2010 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced the Company was awarded two grants, totaling $488,958, under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP). The grants are being provided under section 48D of the Internal Revenue Code, enacted as part of the Patient Protection and Affordable Care Act of 2010. The grants will be used to advance the clinical development of Inspiration's lead product...
LAGUNA NIGUEL, Calif., Nov. 3, 2010 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced the appointment of Karen A. Dawes to the Company's Board of Directors. Ms. Dawes brings to Inspiration over 20 years of healthcare marketing and commercialization experience, including the product launch of the only recombinant factor IX product currently on the market. Ms. Dawes will become the seventh member of Inspiration's Board of Directors. John Taylor, Co-Founder...
HOBOKEN, N.J., Nov. 1, 2010 /PRNewswire/ -- Octapharma AG, one of the largest human protein products manufacturers in the world, and Octapharma USA today announced that patients diagnosed with severe hemophilia A have started treatment in a multi-center study that is researching the use of the first recombinant Factor VIII (rFVIII) derived from a human cell line (Human-cl rhFVIII). Researchers are investigating Human-cl rhFVIII, to assess pharmacokinetics, efficacy, safety and...
WAYNE, N.J., Oct. 26 /PRNewswire/ -- Bayer HealthCare is introducing a fitness program to help children ages 7-12 and young adults ages 13-16 with hemophilia A live active lives. "Living Fit! A Joint Effort" is a unique strength training, fitness and wellness program created to increase awareness of the importance of exercise and nutrition among this population and their caregivers. Fitness and healthy eating are especially important because strong muscles and a lower body weight may help...
LAGUNA NIGUEL, Calif., Oct. 19 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) announced today that the European Commission has granted orphan drug status for OBI-1 for the treatment of hemophilia. Expected to enter pivotal clinical trials before the end of this year, OBI-1 is designed to treat individuals with hemophilia who have developed inhibitors against human Factor VIII (hFVIII). The orphan drug status would trigger a 10-year market exclusivity for OBI-1 in the...
NEW YORK, Aug. 9 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or...
